5 Einträge gefunden

1. Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial

   1. Weisel, Katja
   2. Dimopoulos, Meletios A
   3. San-Miguel, Jesús
   4. Paner, Agne
   5. Engelhardt, Monika
   6. Taylor, Fiona
   7. Lord-Bessen, Jennifer

   2023 - Forschungsinformationssystem des UKE - frei zugänglich
2. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

   1. Mateos, Maria-Victoria
   2. Weisel, Katja
   3. De Stefano, Valerio
   4. Goldschmidt, Hartmut
   5. Delforge, Michel
   6. Mohty, Mohamad
   7. Cavo, Michele

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
3. Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

   1. Chari, Ajai
   2. Munder, Markus
   3. Weisel, Katja
   4. Jenner, Matthew
   5. Bygrave, Ceri
   6. Petrucci, Maria Teresa
   7. Boccadoro, Mario

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
4. Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

   1. Dimopoulos, Meletios A
   2. Niesvizky, Ruben
   3. Weisel, Katja
   4. Siegel, David S
   5. Hajek, Roman
   6. Mateos, María-Victoria
   7. Cavo, Michele

   2020 - Forschungsinformationssystem des UKE
5. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies

   1. Mateos, Maria-Victoria
   2. Spencer, Andrew
   3. Nooka, Ajay K
   4. Pour, Ludek
   5. Weisel, Katja
   6. Cavo, Michele
   7. Laubach, Jacob P

   2020 - Forschungsinformationssystem des UKE